Combining rituximab with mycophenolate for the treatment of interstitial lung disease

Interstitial lung diseases (ILDs) encompass a heterogeneous group of diseases, including autoimmune ILD, hypersensitivity pneumonitis, occupational diseases, granulomatous diseases and idiopathic pneumonitis [1]. Despite their diverse aetiologies, ILDs share common clinical features and are a major contributor to disability and premature death [2]. In recent years, approved and emerging therapies for ILD have increased treatment options for patients [3]. This expanding therapeutic pipeline has created an opportunity to study how combining therapies may improve outcomes for patients with ILD. Combination therapy with rituximab and mycophenolate improves outcomes for patients with interstitial lung disease